Patents Issued in July 4, 2024
  • Publication number: 20240216322
    Abstract: In various embodiments, the present invention provides pharmaceutical compositions comprising fatty acids and methods for treating subjects using same.
    Type: Application
    Filed: March 13, 2024
    Publication date: July 4, 2024
    Inventor: Jonathan Rowe
  • Publication number: 20240216323
    Abstract: Topical dosages and formulations of chloroprocaine and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy, particularly during ophthalmic procedures or in response to ophthalmic abrasions or trauma.
    Type: Application
    Filed: January 8, 2024
    Publication date: July 4, 2024
    Inventors: Augusto Mitidieri, Elisabetta Donati, Clara Bianchi
  • Publication number: 20240216324
    Abstract: The present disclosure provides use of sulforaphene in preparation of a pharmaceutical composition for improving and treating leukotrichia and/or alopecia, and a preparation method of the pharmaceutical composition. The sulforaphene serves as an active ingredient of the pharmaceutical composition, and the sulforaphene has a content of 0.1% to 50% based on a total weight of the pharmaceutical composition.
    Type: Application
    Filed: September 8, 2022
    Publication date: July 4, 2024
    Inventors: Qipeng YUAN, Pengtao LIU, Li CHENG
  • Publication number: 20240216325
    Abstract: The present application relates to a method for inhibiting calcification of aortic valves or inhibiting aortic valve sclerosis/fibrosis. The method involves selecting a subject having, or at risk of developing, calcific aortic valve disease or aortic valve sclerosis/fibrosis and administering, to the selected subject, an inhibitor of the nuclear factor kappa B (NFKB) signaling pathway to inhibit calcification of the selected subject's aortic valves or aortic valve sclerosis/fibrosis.
    Type: Application
    Filed: November 25, 2020
    Publication date: July 4, 2024
    Inventors: Jonathan BUTCHER, Abulajiang MAIHEMUTI, Terrence GEE
  • Publication number: 20240216326
    Abstract: Compositions comprising benzoyl peroxide, azelaic acid, a strontium salt, and methylsulfonylmethane (MSM) are provided, formulated as one or more dosage forms, wherein at least one dosage form comprises both benzoyl peroxide and azelaic acid. These compositions are formulated as cosmetic or medicinal products useful in treating skin diseases, disorders or conditions which may benefit form topical co-administration of BPO and azelaic acid. These skin care products provide dermal shielding against neurogenic inflammation, stinging, itching, burning, redness, irritation, and/or other sensations and feelings associated with topical application of BPO and/or azelaic acid.
    Type: Application
    Filed: April 30, 2022
    Publication date: July 4, 2024
    Inventors: Masha Minkin, Eran Rosman
  • Publication number: 20240216327
    Abstract: The present invention provides compositions and methods for delaying or preventing progression to type 2 diabetes mellitus in individuals with prediabetes and metabolic syndrome.
    Type: Application
    Filed: March 13, 2024
    Publication date: July 4, 2024
    Inventors: Wesley DAY, Barbara TROUPIN
  • Publication number: 20240216328
    Abstract: Disclosed are bruceolides for the treatment of cancer, and oilier diseases, selectively targeting unwanted cells. The disclosed bruceolides may include a site specific cleavable moiety inhibiting the chemotoxic activity until cleaved, i.e., removed, within and/or near a cancer to be treated. As to facilitate selective delivery to cancer tumors, the disclosed bruceolides may be loaded into, attached to or otherwise carried by nanoparticles.
    Type: Application
    Filed: October 19, 2023
    Publication date: July 4, 2024
    Applicant: HOWARD UNIVERSITY
    Inventor: Simeon Kolawole ADESINA
  • Publication number: 20240216329
    Abstract: The present invention describes complex topical aqueous compositions for the effective delivery of active ingredients such as putrescine and Vitamin C into the skin. These compositions may be used in a variety of cosmetic and therapeutic applications including for reducing or preventing skin's signs of aging, for promoting wound healing, for reducing or preventing the formation of hypertrophic scar tissue, for reducing or preventing skin irritation and/or inflammation.
    Type: Application
    Filed: January 26, 2024
    Publication date: July 4, 2024
    Inventor: Ghislain VIVIER
  • Publication number: 20240216330
    Abstract: The present disclosure provides combination therapies for treating an autoimmune disease in a subject in need thereof. The methods comprise administering to the subject an effective amount of a BTK inhibitor in combination with an effective amount of a fumaric acid ester (FAE). The autoimmune disease can be treated include, for example, multiple sclerosis (MS), lupus, rheumatoid arthritis (RA), Pemphigus Vugaris (PV), neuromyelitis optica (NMO), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), anti-NMDA receptor encephalitis, or Sjogren's disease.
    Type: Application
    Filed: April 1, 2022
    Publication date: July 4, 2024
    Inventors: Michael Joseph Palte, Brian T. Hopkins, Matthew P. Scaramozza, Michael Christian Mingueneau, Alex Pellerin, Chelsea R. Parker Harp, Catherine Barbey
  • Publication number: 20240216331
    Abstract: The present invention relates to a composite formulation for oral administration comprising an active pharmaceutical ingredient (API) selected from 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazol-4-carboxylic acid or a pharmaceutically acceptable salt thereof, wherein the API has a particle size of granules corresponding to 90% of the maximum particle size in the cumulative particle size distribution (D(0.9)) of 80 ?m or more and 300 ?m or less. The composite formulation for oral administration according to the present invention has a low friability and an increased dissolution rate even if a high content of API is included, by regulating the particle size of the API to a certain range.
    Type: Application
    Filed: April 15, 2022
    Publication date: July 4, 2024
    Applicant: LG CHEM, LTD.
    Inventors: Seok Cheol YOO, Joomyung JANG, Jin A SEO, Dohyung LIM
  • Publication number: 20240216332
    Abstract: The present application relates to a method and pharmaceutical composition for treating myopia. The pharmaceutical composition or the method of the present application can effectively prevent and control myopia, is safe and has no obvious side effect, and has a good clinical application prospect.
    Type: Application
    Filed: April 29, 2022
    Publication date: July 4, 2024
    Inventors: Xiangtian ZHOU, Miaozhen PAN, Jia QU, Qinyuan ZHENG, Hao WU
  • Publication number: 20240216333
    Abstract: Methods of treating glioblastoma are provided comprising: administering a therapeutically effective amount of azeliragon, or a pharmaceutically acceptable salt thereof, and co-administering an effective amount of radiation therapy (RT), to a patient who has been diagnosed with glioblastoma. In another aspect, methods are provided for treating grade I, grade II, and grade III gliomas, the method comprising administering a therapeutically effective amount of azeliragon, or a pharmaceutically acceptable salt thereof, and co-administering an effective amount of radiation therapy (RT), to a patient who has been diagnosed with glioma.
    Type: Application
    Filed: December 8, 2023
    Publication date: July 4, 2024
    Inventor: Stephen G. Marcus
  • Publication number: 20240216334
    Abstract: The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for treating patients suffering from mydriasis, glaucoma, and other ocular conditions.
    Type: Application
    Filed: April 22, 2022
    Publication date: July 4, 2024
    Inventors: Jay Stuart PEPOSE, Eliot Stuart LAZAR, Mina SOOCH, Alan R. MEYER, Konstantinos CHARIZANIS, Bemhard HOFFMANN, William H. PITLICK
  • Publication number: 20240216335
    Abstract: The present invention aims to provide a composition for increasing leukocytes and/or basophils, a composition for inhibiting epidermal growth factor receptor (EGER) tyrosine kinase, a composition for activating innate immunity, a method of increasing leukocytes and/or basophils, a method of inhibiting epidermal growth factor receptor (EGFR) tyrosine kinase, and a method of activating innate immunity. The present invention relates to a composition for increasing leukocytes and/or basophils, which contains L-ergothioneine or a salt thereof as an active ingredient.
    Type: Application
    Filed: March 25, 2022
    Publication date: July 4, 2024
    Applicant: SUNTORY HOLDINGS LIMITED
    Inventors: Makoto Katsube, Hiroshi Watanabe, Norihito Murayama
  • Publication number: 20240216336
    Abstract: Disclosed are methods for the treatment of immunodeficiency diseases or disorders in subjects in need thereof by administering to the subject an effective amount of a therapeutic agent that results in dissociation of hexokinase 1 (HK1) from the outer membrane of mitochondria and into the cytosol of macrophage cells in the subject and results in inducing a hyperinflammatory response in the subject.
    Type: Application
    Filed: July 28, 2021
    Publication date: July 4, 2024
    Inventors: Hossein Ardehali, Adam De Jesus
  • Publication number: 20240216337
    Abstract: A co-drug or a pharmaceutical salt thereof includes a muscarinic agonist moiety and an alpha2 adrenergic agonist moiety. The muscarinic agonist moiety and the alpha2 adrenergic agonist moiety are connected covalently via a linker, and the link includes an ester bond, an amide bond, a carbamate bond, or a combination thereof.
    Type: Application
    Filed: March 31, 2022
    Publication date: July 4, 2024
    Inventors: Wenkui Ken FANG, Jinsong NI, Rong YANG, Van DINH
  • Publication number: 20240216338
    Abstract: There is provided a pharmaceutical composition comprising the compound N-[(1S)-1-(4-tert-butylphenyl)ethyl]-2-(6,7-difluoro-1H-benzimidazol-1-yl)acetamide, or 5 pharmaceutically acceptable salt thereof, for use in the treatment of pain by topical administration of the composition to a body surface.
    Type: Application
    Filed: May 10, 2022
    Publication date: July 4, 2024
    Inventors: Magnus HALLDIN, Johanna HAGLUND, Bo LASSEN, Eva Maria SJÖSTRÖM, Annika GRIPENHALL, Nicolaas SCHIPPER, Märta SEGERDAHL
  • Publication number: 20240216339
    Abstract: The disclosure provides, in part, a method of treating a neuropsychiatric disorder in a patient in need thereof, comprising administering to the patient an effective amount of an orexin receptor antagonist and further comprising administering to the patient an effective amount of a serotonin 2A receptor agonist or an NMDA receptor antagonist.
    Type: Application
    Filed: June 8, 2022
    Publication date: July 4, 2024
    Applicant: GILGAMESH PHARMACEUTICALS, INC.
    Inventor: Jonathan SPORN
  • Publication number: 20240216340
    Abstract: Oral dosage forms of metaxalone having improved bioavailability in the fed and fasted states, including dosage forms that employ a reduced dose based on such improved bioavailability.
    Type: Application
    Filed: January 10, 2024
    Publication date: July 4, 2024
    Inventors: Mukteeshwar Gande, Robert M. Levy
  • Publication number: 20240216341
    Abstract: The present invention relates to a composition for the prevention or treatment of chronic kidney disease (CKD), comprising compounds that induce the expression of the anti-aging gene klotho. The compounds represented by Chemical Formula 1 according to the invention are highly effective in enhancing the expression of the Klotho gene, a gene associated with aging, and thus can be useful for a pharmaceutical composition or a food composition for the prevention, amelioration or treatment of CKD.
    Type: Application
    Filed: April 1, 2022
    Publication date: July 4, 2024
    Inventor: Dong Ju JUNG
  • Publication number: 20240216342
    Abstract: Provided is a novel preventing and/or treating agent useful for prevention and/or treatment of carnitine deficiency, or a disease for which supplementation of carnitine may have a therapeutic effect. The present invention relates to a medicament for preventing and/or treating carnitine deficiency, or a disease for which supplementation of carnitine may have a therapeutic effect, the medicament comprising a therapeutically effective amount of (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, a salt thereof, or a solvate thereof.
    Type: Application
    Filed: April 27, 2022
    Publication date: July 4, 2024
    Applicant: KOWA COMPANY, LTD.
    Inventors: Ryohei TANIGAWA, Ayumi SAITO, Kaho IKEGAMI
  • Publication number: 20240216343
    Abstract: Disclosed are methods for treating pulmonary hypertension by activating the endothelial intermediate potassium (IK) and endothelial small potassium (SK) channels in a subject in need thereof.
    Type: Application
    Filed: January 3, 2024
    Publication date: July 4, 2024
    Inventor: Swapnil Sonkusare
  • Publication number: 20240216344
    Abstract: Provided herein are thiazolidinedione analogues that are useful for treating non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), diabetes, and other metabolic inflammation-mediated diseases and disorders. Further, provided herein are non-invasive methods and systems for assessing a subject's risk of having NASH. Moreover, provided herein are non-invasive methods and systems for evaluating whether a treatment of NASH is effective.
    Type: Application
    Filed: January 24, 2024
    Publication date: July 4, 2024
    Inventors: Gerard R. COLCA, Howard C. Dittrich, Brian K. Farmer, Gad Cotter, Beth Anne Cotter-Davison
  • Publication number: 20240216345
    Abstract: The present invention relates to the treatment of Dengue virus infection. To gain insight into the molecular and cellular function of the DENV RC, the inventors generated a tagged NS1 DENV replicon in order to identify associated host proteins during active viral replication. This allowed an unprecedented mapping of the NS1-host interactome in a relevant system and the identification of cellular modules targeted by the DENV RC. By combining these proteomics data with gene silencing experiments, they identified a set of Host Dependency Factors (HDFs) and Host Restriction Factors (HRFs) that critically impact DENV infection. More they tested the NGI-1 molecule for its OST complex inhibition properties and showed that this molecule can be used to treat Dengue virus infection. Thus, the invention relates to an inhibitor of the OST complex and/or of the CCT complex and/or of RACK1 for use in the treatment of dengue virus infection in a subject in need thereof.
    Type: Application
    Filed: October 10, 2023
    Publication date: July 4, 2024
    Inventors: Ali AMARA, Laurent MEERTENS, Mohamed HAFIRASSOU
  • Publication number: 20240216346
    Abstract: The present invention includes substituted chromenones that are useful to inhibit the IRE1/XBP-1 pathway. In certain embodiments, the compounds of the invention inhibit IRE1's RNase activity. In other embodiments, the compounds of the invention are useful to treat or prevent a cancer that involve activation of the ER stress response. The invention also relates, in certain aspects, to the discovery that secretory IgM (sIgM) can orchestrate an immunosuppressive microenvironment by recruiting myeloid-derived suppressor cells (MDSCs) into different tumor models, such as but not limited to solid tumors (such as lung cancer) and tumors that have high levels of secreted IgM. In certain embodiments, sIgM produced by B cells or CLL cells can contribute to the accumulation of MDSCs in a tumor. In other embodiments, inhibition of the IRE1/XBP-1 pathway can ablate, minimize, or reduce MDSC levels in a tumor.
    Type: Application
    Filed: October 5, 2023
    Publication date: July 4, 2024
    Inventors: Chih-Chi Andrew Hu, Juan R. Del Valle
  • Publication number: 20240216347
    Abstract: The disclosure relates to formulations of bezuclastinib, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of c-Kit protein kinases and/or mutant c-kit protein kinases.
    Type: Application
    Filed: December 21, 2023
    Publication date: July 4, 2024
    Inventors: Bradley Barnett, Elodie Rosinovsky, Hulya Sahin, Michael M. Crowley
  • Publication number: 20240216348
    Abstract: Provided herein are methods of administering to a peroneal and a tibial nerve of a patient, wherein the methods include: (a) selecting an entry point of an injection needle in a leg of a patient; (b) inserting the injection needle into the patient at the entry point; (c) administering to a sciatic nerve of the patient via the injection needle saline and a pharmaceutical composition; wherein the pharmaceutical composition comprises multivesicular liposomes comprising: at least one amphipathic lipid, at least one neutral lipid, and bupivacaine phosphate, wherein the bupivacaine phosphate is encapsulated within the multivesicular liposome.
    Type: Application
    Filed: January 25, 2024
    Publication date: July 4, 2024
    Inventors: Roy Winston, Mary DiGiorgi
  • Publication number: 20240216349
    Abstract: An improved method is provided for treating a patient having a disorder responsive to PDE-4 inhibition by administering roflumilast. The improvement involves administering the roflumilast topically in a composition having a roflumilast release profile that produces in the patient a flattened plasma concentration time curve and a reduced Cmax relative to oral administration of a PDE4-inhibiting amount of roflumilast. Such disorders include inflammatory disorders such as inflammatory dermatoses, including psoriasis, atopic dermatitis and seborrheic dermatitis. Such disorders also include inflammatory diseases in a variety of organs, especially the lungs (asthma, COPD). Because of reduced side effects with topical administration due to the improved pharmacokinetics (PK) characteristics, it may be possible to provide higher systemic exposures (AUCs) with topical administration, resulting in greater therapeutic efficacy than with the oral route of administration.
    Type: Application
    Filed: March 6, 2024
    Publication date: July 4, 2024
    Applicant: Arcutis Biotherapeutics, Inc.
    Inventor: David Osborne
  • Publication number: 20240216350
    Abstract: The instant invention relates to a semi-solid topical composition containing Pirfenidone and an antimicrobial/antiseptic agent such as Modified Diallyl Disulfide Oxide (M-DDO) and its preparation process, offering advantages compared to other pharmaceutical forms of topical administration known in the state of the art, useful as antifibrotic, anti-inflammatory and antiseptic agent in the prevention, treatment and reversion of acne and post acne lesions. Said compositions is also useful for reducing skin redness, detaining the formation of new acne outbreaks, reversing already existing outbreaks and regenerating skin damage caused by acne.
    Type: Application
    Filed: August 15, 2023
    Publication date: July 4, 2024
    Applicant: Excalibur Pharmaceuticals, Inc.
    Inventors: Juan Socorro Armendáriz Borunda, José Agustín Rogelio Magaña Castro, Pedro Peña Santoyo, Laura Vázquez Cervantes
  • Publication number: 20240216351
    Abstract: The invention provides a method of improving the appearance of aging skin by administering locally to an area of the aging skin of a subject a cosmetic or dermatological composition that includes an effective amount of an adensoine A3 receptor antagonist and a dermatologically acceptable carrier, thereby improving the appearance of the area of the aging skin.
    Type: Application
    Filed: May 3, 2022
    Publication date: July 4, 2024
    Applicant: ORADIN PHARMACEUTICAL LTD.
    Inventors: Lea Levana MADI, Rafi KORENSTEIN
  • Publication number: 20240216352
    Abstract: This disclosure relates to methods of treating interstitial lung disease by administering (1S,3S)-3-((2-methyl-6-(1-methyl-5-(((methyl(propyl)carbamoyl)oxy)methyl)-1H-1,2,3-triazol-4-yl)pyridin-3-yl)oxy)cyclohexane-1-carboxylic acid (a LPA1 antagonist).
    Type: Application
    Filed: December 22, 2023
    Publication date: July 4, 2024
    Inventors: Giridhar S. TIRUCHERAI, Edgar D. CHARLES, Aryeh FISCHER, Shiwei TAO
  • Publication number: 20240216353
    Abstract: The present disclosure is directed to methods of treatment, including treatment of a myopathy by administering to a subject in need thereof an elastase inhibitor in combination with a glucocorticoid. The present disclosure is also directed to pharmaceutical compositions that include an elastase inhibitor that can be used in such treatment.
    Type: Application
    Filed: January 31, 2024
    Publication date: July 4, 2024
    Applicants: The Research Foundation for The State University of New York, The University of Liverpool
    Inventors: Addolorata Pisconti, Fiona Kate Jones, Kirsty Anne Johnson
  • Publication number: 20240216354
    Abstract: The present disclosure provides methods of treating a disease in a subject in need thereof (e.g., proliferative diseases (e.g., cancer (e.g., multiple myeloma))) comprising administering to a subject in need thereof an effective amount of an immunomodulatory drug (e.g., pomalidomide, thalidomide, lenalidomide, iberdomide). The disclosed IMiDs may increase the activity of a kinase (e.g., Zap-70). Also provided are kits comprising the disclosed IMiDs.
    Type: Application
    Filed: October 1, 2020
    Publication date: July 4, 2024
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Teru Hideshima, Kenneth C. Anderson
  • Publication number: 20240216355
    Abstract: The present disclosure relates to a compound of formula I or a pharmaceutically acceptable salt thereof wherein A is X1 is linear or branched C1-6 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, 4-8 membered heterocycloalkyl, wherein X1 is unsubstituted or substituted with one or more of halogen, linear or branched C1-6 alkyl, linear or branched C1-6 heteroalkyl, CF3, CHF2, CMeF2, —O—CHF2, —O—(CH2)2—OMe, OCF3, C1-6 alkylamino, —CN, —N(H)C(O)—C1-6alkyl, —OC(O)—C1-6alkyl, —OC(O)—C1-4alkylamino, —C(O)O—C1-6alkyl, —COOH, —CHO, —C1-6alkylC(O)OH, —C1-6alkylC(O)O—C1-6alkyl, NH2, C1-6 alkoxy or C1-6 alkylhydroxy; or X1 together with X4 forms a 4-8 membered heterocycloalkyl, which is unsubstituted or substituted with one or more of halogen, linear or branched —C1-6 alkyl, CF3, CHF2, CMeF2, —O—(CH2)2—OMe, OCF3, OCHF2, C1-6 alkylamino, —CN, —N(H)C(O)—C1-6alkyl, —OC(O)—C1-6alkyl, —C(O)O—C1-6alkyl, —COOH, —C1-6alkylC(O)OH, —C1-6alkylC(O)O—C1-6alkyl, NH2, C1-4 alkylhydroxy, or C1-6 alkoxy; X2 is hydro
    Type: Application
    Filed: September 21, 2023
    Publication date: July 4, 2024
    Inventors: Bernhard Fasching, Gerald Gavory, Lev Osherovich
  • Publication number: 20240216356
    Abstract: The present disclosure provides a novel palatable pharmaceutical composition in the form of taste-masked 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide hemisuccinate, and orally disintegrating tablets comprising the same. The taste-masked orally disintegrating tablets of this invention will significantly reduce the potently bitter taste of lasmiditan, and enable administration of this product form to migraine patients, in particular pediatric patients and those suffering from nausea due to migraine attacks.
    Type: Application
    Filed: May 6, 2022
    Publication date: July 4, 2024
    Inventors: Matthew Carl Allgeier, Adam Shane Butterbaugh, Robert Louis Ternik
  • Publication number: 20240216357
    Abstract: Provided are a compound represented by general formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer or mixture thereof, a deuterium isotopic derivative, pharmaceutically acceptable hydrate, solvate, salt, or eutectic thereof, a pharmaceutical composition thereof, and an application thereof in preparing a medicament for lysine specific demethylase 1 inhibitor-related diseases.
    Type: Application
    Filed: March 24, 2022
    Publication date: July 4, 2024
    Applicants: SICHUAN HUIYU PHARMACEUTICAL CO., LTD., SICHUAN HUIYU SEACROSS PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventors: Shoujun CHEN, Jiaming YAN, Zhen WANG, Zhao DING
  • Publication number: 20240216358
    Abstract: Provided herein are novel transdermal delivery devices (or patches) comprising dextromethorphan, pharmaceutical compositions comprising dextromethorphan, methods of preparation thereof, and methods of administering dextromethorphan transdermally. Also provided herein are methods of treating various diseases and disorders such as neurological diseases or disorders (e.g., PBA) using the transdermal delivery devices and/or pharmaceutical compositions herein.
    Type: Application
    Filed: March 29, 2021
    Publication date: July 4, 2024
    Inventors: Suresh BORSADIA, Kalpana PATEL, Hock S. TAN, Krunal RAVAL
  • Publication number: 20240216359
    Abstract: This invention relates to methods, compositions and uses of medicaments for treating or ameliorating the symptoms of neurological disorders, such as Parkinson's Disease and Alzheimer's Disease. These purposes can be achieved with formulations of agents for inhibiting or suppressing expression of TGF-?, alone or in combination with formulations of agents based on apomorphine.
    Type: Application
    Filed: March 11, 2024
    Publication date: July 4, 2024
    Inventor: Vuong TRIEU
  • Publication number: 20240216360
    Abstract: Provided herein are drug products adapted for nasal delivery comprising a device and a pharmaceutical composition comprising an opioid receptor antagonist or unit doses thereof, pharmaceutical compositions comprising an opioid receptor antagonist, and methods of use and preparation thereof.
    Type: Application
    Filed: March 12, 2024
    Publication date: July 4, 2024
    Inventors: Gregory G. Plucinski, Adrian T. Raiche, Kristi R. Sims
  • Publication number: 20240216361
    Abstract: Described herein are retinoic acid related-related orphan nuclear receptor (ROR) modulators and methods of utilizing ROR? modulators in the treatment of dermal diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: December 28, 2023
    Publication date: July 4, 2024
    Inventors: Raju MOHAN, John Nuss, Jason Harris
  • Publication number: 20240216362
    Abstract: Provided herein are compounds of Formula (I) or (II) and related compositions and methods for their use as inhibitors of alpha-kinase 1 (ALPK1) and in treating Kawasaki Disease.
    Type: Application
    Filed: April 18, 2022
    Publication date: July 4, 2024
    Inventors: Yuning WEI, Danyang LIU, Cong XU, Lawrence S. MELVIN, Jr., Xiong WEI, Tongruei Raymond LI, Jieqing FAN, Yanfang PAN, Huaixin DANG, Henri LICHENSTEIN, Tian XU
  • Publication number: 20240216363
    Abstract: The pharmaceutical composition according to the present invention is used at specific therapeutic regimen and dosage, and can be usefully used for the prevention or treatment of fibrosis.
    Type: Application
    Filed: May 2, 2022
    Publication date: July 4, 2024
    Inventors: Caroline Hee Lee, Min Jae Cho, Min Young Park, Ju Mi Han, Joon Seok Park
  • Publication number: 20240216364
    Abstract: The present invention relates to a combination of a FXR agonist and a TLR3 agonist having a synergistic effect and its use for the treatment of disease and disorders.
    Type: Application
    Filed: April 28, 2022
    Publication date: July 4, 2024
    Inventors: RAPHAËL DARTEIL, DAVID DURANTEL
  • Publication number: 20240216365
    Abstract: Compositions and methods involving protein disulfide isomerase (PDI) inhibitors, such as protein disulfide isomerase A3 (PDIA3) inhibitory compounds, for human coronavirus, such as severe acute respiratory syndrome (SARS) virus (e.g., SARS-CoV-2), therapies are disclosed herein.
    Type: Application
    Filed: December 15, 2023
    Publication date: July 4, 2024
    Applicant: The University of Vermont and State Agricultural College
    Inventors: Vikas Anathy, Nicolas Chamberlain, Amit Kumar
  • Publication number: 20240216366
    Abstract: The present invention relates to a pharmaceutical composition comprising the calcium; {4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}acetate, in particular to long-acting injectables comprising the same, the use of the pharmaceutical composition for the treatment or prevention of specific diseases, and a process to produce it.
    Type: Application
    Filed: February 7, 2024
    Publication date: July 4, 2024
    Inventors: Katie AMSSOMS, Eddy DE PROOST, Wenyu DONG, Paul HARTMAN KOK, Rene HOLM, Kristof KIMPE, Greet MEURS, Maxim VERSTRAETEN
  • Publication number: 20240216367
    Abstract: Provided are methods for treating various spondyloarthritic and psoriatic conditions, including types of axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and psoriasis (PsO), with the JAK1 inhibitor, upadacitinib free base or pharmaceutically acceptable salt thereof. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA), methods for treating active ankylosing spondylitis (AS), methods for treating active psoriatic arthritis (PsA), and methods for treating active psoriasis (PsO).
    Type: Application
    Filed: August 4, 2023
    Publication date: July 4, 2024
    Inventors: Aileen L. Pangan, Jaclyn Kay Anderson, In-Ho Song, Jose Jeffrey V. Enejosa
  • Publication number: 20240216368
    Abstract: The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.
    Type: Application
    Filed: March 12, 2024
    Publication date: July 4, 2024
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng LI, Robert DAVIS
  • Publication number: 20240216369
    Abstract: Use of a splicing modulator for a treatment slowing progression of Huntington's disease.
    Type: Application
    Filed: October 30, 2020
    Publication date: July 4, 2024
    Inventors: Martin BEIBEL, Beth BOROWSKY, Jang-Ho CHA, Thomas FALLER, Baltazar GOMEZ-MANCILLA, Caroline GUBSER KELLER, Marc LAISNEY, Wen LIN, Nicole RENAUD, Rajeev SIVASANKRAN
  • Publication number: 20240216370
    Abstract: The present invention relates to methods for treating or preventing vascularisation in one or both corneas of a subject. The methods comprise topically administering an effective amount of a composition comprising dasatinib to one or both eyes of the subject. The method is particularly useful for treating subjects with corneal vascularisation associated with ocular pterygium-digital keloid dysplasia (OPDKD), Warburg-Cinotti syndrome (WCS) or Penttinen syndrome, and other conditions caused by activating mutations in PDGFR? and DDR2.
    Type: Application
    Filed: February 18, 2021
    Publication date: July 4, 2024
    Inventors: Cecilie BREDRUP, Ove BRULAND, Eyvind RØDAHL, Gunnar HOUGE
  • Publication number: 20240216371
    Abstract: A hair regrowth composition including in combination one part by weight 5% solution of 2,4-diamino-6-piperidinopyrimidine and one part by weight admixture. The admixture further includes one part by weight biotin, one part by weight rosemary oil, one part by weight tea tree oil, one part by weight peppermint oil, and one part by weight pumpkinseed oil.
    Type: Application
    Filed: January 4, 2023
    Publication date: July 4, 2024
    Inventor: Neema Mayenga